17³Ô¹ÏÔÚÏß Stands Up for Biopharmaceutical Innovation Before Senate Hearing
In advance of a Senate hearing on health care costs, the 17³Ô¹ÏÔÚÏß is ensuring that senators understand the importance of biopharmaceutical innovation to patients and the U.S. economy—and the damaging impact of policies that hinder drug development.
What’s happening: The Senate Armed Services Committee will hold a subcommittee hearing today on whether harmful policies like price controls, compulsory licensing and weaker intellectual property protections for new medicines could reduce servicemembers’ health care costs.
17³Ô¹ÏÔÚÏß pushes back: The 17³Ô¹ÏÔÚÏß is highlighting the extraordinary investment—in both time and capital—that it takes to bring a lifesaving treatment to market. According to the :
- The average cost of developing a new drug was $2.3 billion as of 2022;
- Across the industry, biopharmaceutical manufacturers spent $139 billion on R&D in just 2022 alone;
- It can take 10 to 15 years for a breakthrough scientific discovery to move through early-stage research, clinical trials, Food and Drug Administration approval and manufacturing; and
- Only 12% of investigational drugs that enter a Phase I clinical trial ultimately receive FDA approval—to say nothing of the hundreds of discoveries that never make it into clinical trials.
Lifesaving impact: In 2023, the FDA approved a record-breaking 71 new medicines that will improve the lives of patients.
- The biopharmaceutical industry behind these breakthroughs is also stimulating the U.S. economy: Biopharmaceutical manufacturers accounted for $355 billion in value-added output to the U.S. economy in 2021 and directly employed 291,000 workers in the U.S.
Innovation under threat: In recent years, biopharmaceutical manufacturers have been subject to harmful policies that will limit innovation and slow efforts to develop lifesaving medicines.
Read the full story .